language_icon
EN
HI

Senores Pharmaceuticals Share price

SENORES

1165.15

11.50 (1.00%)
NSE
BSE
Last updated on 26 May, 2026 | 14:56 IST
Today's High

1173.80

Today's Low

1141.00

52 Week Low

499.55

52 Week High

1194.40

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Senores Pharmaceuticals Chart

Senores Pharmaceuticals Share Key Metrics

Volume
1.86 L
Market Cap
5312.97 CR
LTQ@LTP
1@1165.15
ATP
1156.86
Var Margin
20.08 %
Circuit Range
922.95-1384.35
Delivery %
43.85 %
Value
21.56 CR
ASM/GSM
No
Market Lot
1

Summary

Senores Pharmaceuticals share price is ₹1165.15 as of 26 May, 2026. The stock Senores Pharmaceuticals intraday movement has stayed between ₹1141.00 and ₹1173.80, while on a 52-week basis,Senores Pharmaceuticals price 52 week high is ₹1194.40 & its 52 week low is ₹499.55.
In terms of trading activity, Senores Pharmaceuticals has recorded a volume of 186365 shares, The Senores Pharmaceuticals has a market cap of ₹46053588 CR. The stock’s Average Traded Price (ATP) stands at ₹1156.86, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1 @ ₹1165.15.
Senores Pharmaceuticals operates within a circuit range of ₹922.95 – ₹1384.35, with a Value of ₹21.56 CR. The Delivery Percentage for the day is 43.85%. Additionally, Senores Pharmaceuticals currently falls under the No framework, and trades with a market lot size of 1.

Senores Pharmaceuticals Fundamentals

View More
P/E Ratio

45.95

P/B Ratio

5.68

Div. Yield

0

Sector P/E

71.09

Sector P/B

3.48

Sec. Div. Yield

0.55

Senores Pharmaceuticals Resistance and Support

Pivot 1143

Resistance

First Resistance

1170.65

Second Resistance

1187.65

Third Resistance

1215.3

Support

First Support

1126

Second Support

1098.35

Third Support

1081.35

Senores Pharmaceuticals Shareholding Pattern

View More
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

45.82%

Mutual Fund

5.07%

Insurance

2.96%

Foreign Institutional Investors

3.64%

Domestic Institutional Investors

1.58%

Retail

40.93%

Others

0%

Total Promoters
MAR '26
45.82%

Senores Pharmaceuticals Corporate Actions

DateAgenda
2026-05-14Audited Results
2026-01-20Quarterly Results & Others
2026-01-07Others
2025-11-06Quarterly Results
2025-07-23Quarterly Results & Others
2025-05-15Audited Results
2025-01-23Quarterly Results & Others

Senores Pharmaceuticals News

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Senores Pharmaceuticals will attend an analyst and institutional investor meeting hosted by Ambit Capital on May 25, 2026. Discussions will cover publicly available information.
May 20 2026 11:20:52

Senores Pharmaceuticals Limited

Senores Pharma reported strong Q4 FY26 revenue of Rs.190 crore, up 66% YoY, and PAT of Rs.32 crore, up 78% YoY. Full-year FY26 revenue increased 62% to Rs.664 crore, with PAT doubling to Rs.122 crore. The company guides for 30-40% revenue growth and 50-60% PAT growth for FY27.
May 19 2026 17:09:47

Senores Pharmaceuticals Ltd - 544319 - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On March 31, 2026

Senores Pharma provided an update on the utilization of its Rs. 500 crore IPO funds. A Rs. 33.02 crore capex for its subsidiary, Havix, is delayed to FY27 due to geopolitical issues. Additionally, Rs. 6.31 crore from offer expenses and Rs. 0.40 crore from debt repayment were re-allocated to general corporate purposes and inorganic growth.
May 14 2026 15:59:40

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Senores Pharmaceuticals' Q4 FY26 Monitoring Agency Report highlights delays in deploying IPO proceeds. Significant delays include Rs. 33.02 cr for a manufacturing facility, now extended to FY27, and working capital investments. Funds have been re-allocated between various objectives.
May 14 2026 15:27:28

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Senores Pharmaceuticals released its Q4 and FY26 financial results via a media release, reporting strong performance. Q4 total income increased by 66% to Rs.190 crore and PAT rose 104% to Rs.37 crore. The company also announced strategic acquisitions of Zoraya and Apnar Pharmaceuticals, and a new joint venture in the U.S. Federal Market.
May 14 2026 14:31:21

Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 14, 2026

Senores Pharma announced strong Q4 FY26 and full-year FY26 consolidated financial results. Q4 total income grew 66% to ₹190 Cr, EBITDA surged 219% to ₹62 Cr, and PAT increased 104% to ₹37 Cr. The company completed 75% stake acquisition in Apnar Pharmaceuticals and formed a 70% JV, Amerisyn, for the US federal market.
May 14 2026 14:13:34

Senores Pharmaceuticals Ltd - 544319 - Board Meeting Intimation for Considering And Approving The Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And To Transact Other Business Matters

Senores Pharmaceuticals board is scheduled to meet on May 14, 2026. The primary agenda is to consider and approve the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026.
May 08 2026 17:08:22
Read More

Senores Pharmaceuticals Management

NamePosition
Vinay Kumar MishraCompany Secretary & Compliance Officer
Swapnil Jatinbhai ShahManaging Director
View More

Senores Pharmaceuticals FAQs

The Buying Price of Senores Pharmaceuticals share is 1165.15 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Senores Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Senores Pharmaceuticals, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Senores Pharmaceuticals shares is 45.95. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Senores Pharmaceuticals shares is 5.68. Useful to assess the stock's value relative to its book value.

To assess Senores Pharmaceuticals’s valuation compare Sector P/E, P/B which are 71.09 & 3.48 with sector averages, along with growth rates and financial metrics.

The Market Cap of Senores Pharmaceuticals is 5312.97 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Senores Pharmaceuticals share price is 1194.40 & 499.55. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Senores Pharmaceuticals belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost